Clene Inc. (NASDAQ: CLNN) Applies Patented Nanotechnology to Development of CNM-Au8(R), its Investigational Drug for ALS
In line with recent emphasis on the growing importance of nanotechnology in the US, Clene Nanomedicine innovated its investigational drug, CNM-Au8(R), using nanotechnology for the treatment of neurodegenerative disease Clene’s nanotechnological approach was recently recognized by the NINDS of NIH with a substantial grant to conduct an Expanded Access Protocol in ALS with CNM-Au8(R) Clene aims to file a New Drug Application for CNM-Au8(R) for ALS indications in the first half of 2024 October 2023 has turned into a month for the celebration of nanotechnology. On Wednesday, Oct. 4, 2023, three U.S.-based scientists, Moungi Bawendi, Louis Brus, and Aleksey Ekimov,…